Correlation of serum ESR1 methylation levels with RE status in tumor and molecular subtypes of breast cancer.

Abstract

e13648 Background: To determine whether estrogen receptor (ER) (+) and ER (-) status relates to epigenetic changes in breast cancer-related genes and to correlate with molecular breast cancer subtypes. Methods: From January 2002 to June 2005, we quantified methylation levels ERS1 gene in serum of 92 pts breast cancer. A PCR quantitative technique was used to analyze levels of methylation gene. We also examined and correlationed the expression of ESR1 AND HER2+ in tumors by immunohistochemistry with molecular phenotype. Results: Median age was 58 years (32-88); 69% were postmenopausal women. Nodal involvement (N0;63%,N1;30%,N2;7%), tumor size (T1;58%, T2;35%, T3;4%, T4;4%) and grade (G1;20%, G2;37%, G3;30%). Of the cases, 37pts (40%) were Luminal A (LA), 32pts (33%) Luminal B (LB), 14pts (15%) triple-negative (TN), and 9pts (10%) HER2+. The methylated ESR1 in serum was significantly associated with ER(-) in breast tumors >80% (p=0.0179). Methylation ESR1 was preferably associated with TN (80%) and HER2+ (60%) subtype. Nevertheless unmethylation ESR1 was found more frequently in LA (71%) and LB (59%) phenotype. With a median follow up of 5 years, we found worse overall survival (OS) with more frequent ESR1 methylation gene (p>0.05), Luminal A; ESR1 Methylation OS at 5 years 81% vs. 93% when was ESR1 Unmethylation. Luminal B; ESR1 Methylation 86% SG at 5 years vs. 92% in Unmethylation ESR1. Triple negative; ESR1 Methylation SG at 5 years 75% vs. 80% in unmethylation ESR1. HER2; ESR1 Methylation SG at 5 years was 66.7% vs. 75% in unmethylation ESR1. Conclusions: Gene promoter region hypermethylation is a significant event in primary breast cancer. However, its impact on tumor progression and potential predictive implications remain relatively unknown. Our study identifies the presence of variations in global levels of methylation promoters ESR1 genes in breast cancer with different phenotype classes and shows that these differences have clinical significance. Although numerous issues remain to be resolved, quantitative measurement of circulating methylated DNA may be of significance in the assessment and search of targeted therapy resistance related to ESR1 and HER2 status by epigenetic or transcriptional cancer therapy No significant financial relationships to disclose.